Lophius Biosciences Launches Interactive T Cell Tools Product Finder and Online Order Portal
Lophius Biosciences GmbH, a privately held biotech company focusing on the development and marketing of innovative T cell-based research tools and diagnostic systems for functional assessment of pathogen/disease-reactive T cells, has launched of its new T Cell Tools product line together with its new e-commerce online order portal. The new web-based customer interface at www.Lophius.com has been designed to provide an intuitive product selection and online order platform accelerating the ability of customers to quickly identify and select products from Lophius’ continuously growing portfolio.
T Cell Tools comprise selected research reagents to allow easy and reliable T cell stimulation, as well as robust quantification and monitoring of cell mediated immune responses (CMI). Different antigens from various pathogens with a current focus on the human cytomegalovirus (HCMV) and Epstein-Barr Virus (EBV) are well coordinated and validated to jointly contribute to a standardized and reliable read-out system. Hence, the individual product modules of T Cell Tools offer modular and complementary solutions for optimal assay performance.
Today, T Cell Tools include, amongst, peptide pools, lysates an proteins, a panel of T-activated antigens - complete proteins that are formulated using Lophius’ proprietary T-activation technology platform facilitating uptake and processing of the proteins via the canonical MHC class-I cross-presentation pathway. As a result, clinically relevant effector cells of the CMI such as CD4- and CD8-positve T cells as well as NK, and NKT cells will be activated. Optionally, customers may also combine their antigens with a matching IFN-gamma ELISPOT T-Track basic kit to reach maximum sensitivity and specificity upon measuring pathogen specific T cells.
Lophius aims to quickly expand the panel of antigens, antibodies, conjugates and read-out options to offer its customers a very comprehensive panel of relevant and well coordinated tools in near future to booster T cell research. Customers include researchers and clinicians in the field of immunology, infectious diseases, transplantation, clinical virology, oncology, autoimmune diseases, gynecology, and intensive care who need optimal performance by using either the standardized in-vitro diagnostic kit T-Track CMV or an individually compiled T cell activity assay based on the robust T-Track technology.
“We are very excited to announce the launch of our e-commerce portal as we believe it will provide our customers greater access to Lophius’ products at their convenience,” said Dr Robert Phelps, CEO of Lophius Biosciences. “With our intuitive product finder, consumers can browse and order some of the most innovative T cell products on the market” added Prof. Ralf Wagner, Chairman of the Board.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...